ID   GSK3B_HUMAN             Reviewed;         420 AA.
AC   P49841; D3DN89; Q9BWH3; Q9UL47;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   02-MAY-2002, sequence version 2.
DT   22-JUL-2015, entry version 194.
DE   RecName: Full=Glycogen synthase kinase-3 beta;
DE            Short=GSK-3 beta;
DE            EC=2.7.11.26;
DE   AltName: Full=Serine/threonine-protein kinase GSK3B;
DE            EC=2.7.11.1;
GN   Name=GSK3B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF SER-9.
RX   PubMed=7980435;
RA   Stambolic V., Woodgett J.R.;
RT   "Mitogen inactivation of glycogen synthase kinase-3 beta in intact
RT   cells via serine 9 phosphorylation.";
RL   Biochem. J. 303:701-704(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Eye, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-28.
RX   PubMed=10486203; DOI=10.1006/geno.1999.5875;
RA   Lau K.F., Miller C.C.J., Anderton B.H., Shaw P.C.;
RT   "Molecular cloning and characterization of the human glycogen synthase
RT   kinase-3beta promoter.";
RL   Genomics 60:121-128(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 185-202.
RX   PubMed=10523816; DOI=10.1038/sj.mp.4000538;
RA   Rhoads A.R., Karkera J.D., Detera-Wadleigh S.D.;
RT   "Radiation hybrid mapping of genes in the lithium-sensitive wnt
RT   signaling pathway.";
RL   Mol. Psychiatry 4:437-442(1999).
RN   [6]
RP   FUNCTION IN PHOSPHORYLATION OF JUN.
RX   PubMed=1846781; DOI=10.1016/0092-8674(91)90241-P;
RA   Boyle W.J., Smeal T., Defize L.H., Angel P., Woodgett J.R., Karin M.,
RA   Hunter T.;
RT   "Activation of protein kinase C decreases phosphorylation of c-Jun at
RT   sites that negatively regulate its DNA-binding activity.";
RL   Cell 64:573-584(1991).
RN   [7]
RP   FUNCTION IN PHOSPHORYLATION OF EIF2BE/EIF2B5.
RX   PubMed=8397507;
RA   Welsh G.I., Proud C.G.;
RT   "Glycogen synthase kinase-3 is rapidly inactivated in response to
RT   insulin and phosphorylates eukaryotic initiation factor eIF-2B.";
RL   Biochem. J. 294:625-629(1993).
RN   [8]
RP   PHOSPHORYLATION AT SER-9.
RX   PubMed=8250835;
RA   Sutherland C., Leighton I.A., Cohen P.;
RT   "Inactivation of glycogen synthase kinase-3 beta by phosphorylation:
RT   new kinase connections in insulin and growth-factor signalling.";
RL   Biochem. J. 296:15-19(1993).
RN   [9]
RP   ENZYME REGULATION BY AKT1.
RX   PubMed=8524413; DOI=10.1038/378785a0;
RA   Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A.;
RT   "Inhibition of glycogen synthase kinase-3 by insulin mediated by
RT   protein kinase B.";
RL   Nature 378:785-789(1995).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF NFATC1/NFATC.
RX   PubMed=9072970; DOI=10.1126/science.275.5308.1930;
RA   Beals C.R., Sheridan C.M., Turck C.W., Gardner P., Crabtree G.R.;
RT   "Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3.";
RL   Science 275:1930-1934(1997).
RN   [11]
RP   INTERACTION WITH DNM1L.
RC   TISSUE=Liver;
RX   PubMed=9731200; DOI=10.1006/bbrc.1998.9253;
RA   Hong Y.-R., Chen C.-H., Cheng D.-S., Howng S.-L., Chow C.-C.;
RT   "Human dynamin-like protein interacts with the glycogen synthase
RT   kinase 3beta.";
RL   Biochem. Biophys. Res. Commun. 249:697-703(1998).
RN   [12]
RP   INTERACTION WITH MUC1, AND FUNCTION.
RX   PubMed=9819408;
RA   Li Y., Bharti A., Chen D., Gong J., Kufe D.;
RT   "Interaction of glycogen synthase kinase 3beta with the DF3/MUC1
RT   carcinoma-associated antigen and beta-catenin.";
RL   Mol. Cell. Biol. 18:7216-7224(1998).
RN   [13]
RP   CHARACTERIZATION.
RX   PubMed=9736715; DOI=10.1073/pnas.95.19.11211;
RA   Delcommenne M., Tan C., Gray V., Rue L., Woodgett J.R., Dedhar S.;
RT   "Phosphoinositide-3-OH kinase-dependent regulation of glycogen
RT   synthase kinase 3 and protein kinase B/AKT by the integrin-linked
RT   kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:11211-11216(1998).
RN   [14]
RP   INTERACTION WITH NIN.
RX   PubMed=11004522; DOI=10.1016/S0167-4781(00)00127-5;
RA   Hong Y.-R., Chen C.-H., Chang J.-H., Wang S.-K., Sy W.-D., Chou C.-K.,
RA   Howng S.-L.;
RT   "Cloning and characterization of a novel human ninein protein that
RT   interacts with the glycogen synthase kinase 3beta.";
RL   Biochim. Biophys. Acta 1492:513-516(2000).
RN   [15]
RP   ASSOCIATION WITH DIABETES MELLITUS.
RX   PubMed=10868943; DOI=10.2337/diabetes.49.2.263;
RA   Nikoulina S.E., Ciaraldi T.P., Mudaliar S., Mohideen P., Carter L.,
RA   Henry R.R.;
RT   "Potential role of glycogen synthase kinase-3 in skeletal muscle
RT   insulin resistance of type 2 diabetes.";
RL   Diabetes 49:263-271(2000).
RN   [16]
RP   FUNCTION, AND MUTAGENESIS OF ARG-96 AND LEU-128.
RX   PubMed=11430833; DOI=10.1016/S1097-2765(01)00253-2;
RA   Frame S., Cohen P., Biondi R.M.;
RT   "A common phosphate binding site explains the unique substrate
RT   specificity of GSK3 and its inactivation by phosphorylation.";
RL   Mol. Cell 7:1321-1327(2001).
RN   [17]
RP   PHOSPHORYLATION AT SER-9 BY SGK3, AND INTERACTION WITH SGK3.
RX   PubMed=12054501; DOI=10.1016/S0006-291X(02)00349-2;
RA   Dai F., Yu L., He H., Chen Y., Yu J., Yang Y., Xu Y., Ling W.,
RA   Zhao S.;
RT   "Human serum and glucocorticoid-inducible kinase-like kinase (SGKL)
RT   phosphorylates glycogen syntheses kinase 3 beta (GSK-3beta) at serine-
RT   9 through direct interaction.";
RL   Biochem. Biophys. Res. Commun. 293:1191-1196(2002).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF MAPT/TAU.
RX   PubMed=14690523;
RA   Cho J.H., Johnson G.V.;
RT   "Primed phosphorylation of tau at Thr231 by glycogen synthase kinase
RT   3beta (GSK3beta) plays a critical role in regulating tau's ability to
RT   bind and stabilize microtubules.";
RL   J. Neurochem. 88:349-358(2004).
RN   [19]
RP   FUNCTION, INTERACTION WITH SNAI1, AND SUBCELLULAR LOCATION.
RX   PubMed=15448698; DOI=10.1038/ncb1173;
RA   Zhou B.P., Deng J., Xia W., Xu J., Li Y.M., Gunduz M., Hung M.C.;
RT   "Dual regulation of Snail by GSK-3beta-mediated phosphorylation in
RT   control of epithelial-mesenchymal transition.";
RL   Nat. Cell Biol. 6:931-940(2004).
RN   [20]
RP   INTERACTION WITH CABYR.
RX   PubMed=15752768; DOI=10.1016/j.bbrc.2005.02.089;
RA   Hsu H.-C., Lee Y.-L., Cheng T.-S., Howng S.-L., Chang L.-K., Lu P.-J.,
RA   Hong Y.-R.;
RT   "Characterization of two non-testis-specific CABYR variants that bind
RT   to GSK3beta with a proline-rich extensin-like domain.";
RL   Biochem. Biophys. Res. Commun. 329:1108-1117(2005).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH SNAI1.
RX   PubMed=15647282; DOI=10.1074/jbc.M413878200;
RA   Yook J.I., Li X.Y., Ota I., Fearon E.R., Weiss S.J.;
RT   "Wnt-dependent regulation of the E-cadherin repressor snail.";
RL   J. Biol. Chem. 280:11740-11748(2005).
RN   [22]
RP   INTERACTION WITH PRUNE.
RX   PubMed=16428445; DOI=10.1128/MCB.26.3.898-911.2006;
RA   Kobayashi T., Hino S., Oue N., Asahara T., Zollo M., Yasui W.,
RA   Kikuchi A.;
RT   "Glycogen synthase kinase 3 and h-prune regulate cell migration by
RT   modulating focal adhesions.";
RL   Mol. Cell. Biol. 26:898-911(2006).
RN   [23]
RP   FUNCTION, AND PHOSPHORYLATION AT SER-9.
RX   PubMed=16484495; DOI=10.1126/science.1121613;
RA   Yin L., Wang J., Klein P.S., Lazar M.A.;
RT   "Nuclear receptor Rev-erbalpha is a critical lithium-sensitive
RT   component of the circadian clock.";
RL   Science 311:1002-1005(2006).
RN   [24]
RP   INTERACTION WITH AXIN1.
RX   PubMed=17318175; DOI=10.1038/sj.emboj.7601607;
RA   Luo W., Peterson A., Garcia B.A., Coombs G., Kofahl B., Heinrich R.,
RA   Shabanowitz J., Hunt D.F., Yost H.J., Virshup D.M.;
RT   "Protein phosphatase 1 regulates assembly and function of the beta-
RT   catenin degradation complex.";
RL   EMBO J. 26:1511-1521(2007).
RN   [25]
RP   FUNCTION IN PHOSPHORYLATION OF SIK1.
RX   PubMed=18348280; DOI=10.1002/jcb.21737;
RA   Hashimoto Y.K., Satoh T., Okamoto M., Takemori H.;
RT   "Importance of autophosphorylation at Ser186 in the A-loop of salt
RT   inducible kinase 1 for its sustained kinase activity.";
RL   J. Cell. Biochem. 104:1724-1739(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-402, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-390, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [28]
RP   INTERACTION WITH MMP2.
RX   PubMed=19493954; DOI=10.1093/cvr/cvp175;
RA   Kandasamy A.D., Schulz R.;
RT   "Glycogen synthase kinase-3beta is activated by matrix
RT   metalloproteinase-2 mediated proteolysis in cardiomyoblasts.";
RL   Cardiovasc. Res. 83:698-706(2009).
RN   [29]
RP   FUNCTION, AND INTERACTION WITH CLOCK-ARNTL/BMAL1.
RX   PubMed=19946213;
RA   Spengler M.L., Kuropatwinski K.K., Schumer M., Antoch M.P.;
RT   "A serine cluster mediates BMAL1-dependent CLOCK phosphorylation and
RT   degradation.";
RL   Cell Cycle 8:4138-4146(2009).
RN   [30]
RP   INTERACTION WITH CTNND2.
RX   PubMed=19706605; DOI=10.1074/jbc.M109.002659;
RA   Oh M., Kim H., Yang I., Park J.H., Cong W.T., Baek M.C., Bareiss S.,
RA   Ki H., Lu Q., No J., Kwon I., Choi J.K., Kim K.;
RT   "GSK-3 phosphorylates delta-catenin and negatively regulates its
RT   stability via ubiquitination/proteosome-mediated proteolysis.";
RL   J. Biol. Chem. 284:28579-28589(2009).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [33]
RP   ALTERNATIVE SPLICING.
RX   PubMed=20067585; DOI=10.1111/j.1471-4159.2010.06581.x;
RA   Castano Z., Gordon-Weeks P.R., Kypta R.M.;
RT   "The neuron-specific isoform of glycogen synthase kinase-3beta is
RT   required for axon growth.";
RL   J. Neurochem. 113:117-130(2010).
RN   [34]
RP   FUNCTION.
RX   PubMed=20932480; DOI=10.1016/j.molcel.2010.09.013;
RA   Heyd F., Lynch K.W.;
RT   "Phosphorylation-dependent regulation of PSF by GSK3 controls CD45
RT   alternative splicing.";
RL   Mol. Cell 40:126-137(2010).
RN   [35]
RP   INTERACTION WITH DAB2IP AND PPP2CA.
RX   PubMed=20080667; DOI=10.1073/pnas.0908133107;
RA   Xie D., Gore C., Liu J., Pong R.C., Mason R., Hao G., Long M.,
RA   Kabbani W., Yu L., Zhang H., Chen H., Sun X., Boothman D.A., Min W.,
RA   Hsieh J.T.;
RT   "Role of DAB2IP in modulating epithelial-to-mesenchymal transition and
RT   prostate cancer metastasis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:2485-2490(2010).
RN   [36]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-9.
RX   PubMed=20937854; DOI=10.1073/pnas.1000975107;
RA   Zaoui K., Benseddik K., Daou P., Salaun D., Badache A.;
RT   "ErbB2 receptor controls microtubule capture by recruiting ACF7 to the
RT   plasma membrane of migrating cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:18517-18522(2010).
RN   [37]
RP   REVIEW ON FUNCTION, AND ENZYME REGULATION.
RX   PubMed=11749387; DOI=10.1021/cr000110o;
RA   Ali A., Hoeflich K.P., Woodgett J.R.;
RT   "Glycogen synthase kinase-3: properties, functions, and regulation.";
RL   Chem. Rev. 101:2527-2540(2001).
RN   [38]
RP   REVIEW ON FUNCTION.
RX   PubMed=17478001; DOI=10.1016/j.diabres.2007.01.033;
RA   Lee J., Kim M.S.;
RT   "The role of GSK3 in glucose homeostasis and the development of
RT   insulin resistance.";
RL   Diabetes Res. Clin. Pract. 77:S49-S57(2007).
RN   [39]
RP   REVIEW ON FUNCTION, AND ENZYME REGULATION.
RX   PubMed=19366350; DOI=10.1111/j.1476-5381.2008.00085.x;
RA   Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A.;
RT   "Glycogen synthase kinase 3: more than a namesake.";
RL   Br. J. Pharmacol. 156:885-898(2009).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [41]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [42]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PHOSPHORYLATION.
RX   PubMed=21029237; DOI=10.1111/j.1750-3639.2010.00437.x;
RA   Bose A., Mouton-Liger F., Paquet C., Mazot P., Vigny M., Gray F.,
RA   Hugon J.;
RT   "Modulation of tau phosphorylation by the kinase PKR: implications in
RT   Alzheimer's disease.";
RL   Brain Pathol. 21:189-200(2011).
RN   [43]
RP   FUNCTION.
RX   PubMed=22514281; DOI=10.1074/jbc.M111.306373;
RA   Sun L., Lv F., Guo X., Gao G.;
RT   "Glycogen synthase kinase 3? (GSK3?) modulates antiviral activity of
RT   zinc-finger antiviral protein (ZAP).";
RL   J. Biol. Chem. 287:22882-22888(2012).
RN   [44]
RP   ADP-RIBOSYLATION BY PARP10.
RX   PubMed=23332125; DOI=10.1186/1478-811X-11-5;
RA   Feijs K.L., Kleine H., Braczynski A., Forst A.H., Herzog N.,
RA   Verheugd P., Linzen U., Kremmer E., Luscher B.;
RT   "ARTD10 substrate identification on protein microarrays: regulation of
RT   GSK3beta by mono-ADP-ribosylation.";
RL   Cell Commun. Signal. 11:5-5(2013).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [46]
RP   FUNCTION, INTERACTION WITH NCYM, AND PHOSPHORYLATION AT SER-9.
RX   PubMed=24391509; DOI=10.1371/journal.pgen.1003996;
RA   Suenaga Y., Islam S.M., Alagu J., Kaneko Y., Kato M., Tanaka Y.,
RA   Kawana H., Hossain S., Matsumoto D., Yamamoto M., Shoji W., Itami M.,
RA   Shibata T., Nakamura Y., Ohira M., Haraguchi S., Takatori A.,
RA   Nakagawara A.;
RT   "NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein
RT   that inhibits GSK3beta resulting in the stabilization of MYCN in human
RT   neuroblastomas.";
RL   PLoS Genet. 10:E1003996-E1003996(2014).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 35-386.
RX   PubMed=11440715; DOI=10.1016/S0092-8674(01)00374-9;
RA   Dajani R., Fraser E., Roe S.M., Young N., Good V., Dale T.C.,
RA   Pearl L.H.;
RT   "Crystal structure of glycogen synthase kinase 3 beta: structural
RT   basis for phosphate-primed substrate specificity and autoinhibition.";
RL   Cell 105:721-732(2001).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 27-393 OF PHOSPHORYLATED
RP   GSK3B.
RX   PubMed=11738041; DOI=10.1016/S0969-2126(01)00679-7;
RA   Bax B., Carter P.S., Lewis C., Guy A.R., Bridges A., Tanner R.,
RA   Pettman G., Mannix C., Culbert A.A., Brown M.J.B., Smith D.G.,
RA   Reith A.D.;
RT   "The structure of phosphorylated GSK-3beta complexed with a peptide,
RT   FRATtide, that inhibits beta-catenin phosphorylation.";
RL   Structure 9:1143-1152(2001).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 35-384 IN COMPLEX WITH AXIN1,
RP   INTERACTION WITH AXIN1 AND FRAT1, FUNCTION, ENZYME REGULATION, AND
RP   PHOSPHORYLATION AT TYR-216.
RX   PubMed=12554650; DOI=10.1093/emboj/cdg068;
RA   Dajani R., Fraser E., Roe S.M., Yeo M., Good V.M., Thompson V.,
RA   Dale T.C., Pearl L.H.;
RT   "Structural basis for recruitment of glycogen synthase kinase 3beta to
RT   the axin-APC scaffold complex.";
RL   EMBO J. 22:494-501(2003).
CC   -!- FUNCTION: Constitutively active protein kinase that acts as a
CC       negative regulator in the hormonal control of glucose homeostasis,
CC       Wnt signaling and regulation of transcription factors and
CC       microtubules, by phosphorylating and inactivating glycogen
CC       synthase (GYS1 or GYS2), EIF2B, CTNNB1/beta-catenin, APC, AXIN1,
CC       DPYSL2/CRMP2, JUN, NFATC1/NFATC, MAPT/TAU and MACF1. Requires
CC       primed phosphorylation of the majority of its substrates. In
CC       skeletal muscle, contributes to insulin regulation of glycogen
CC       synthesis by phosphorylating and inhibiting GYS1 activity and
CC       hence glycogen synthesis. May also mediate the development of
CC       insulin resistance by regulating activation of transcription
CC       factors. Regulates protein synthesis by controlling the activity
CC       of initiation factor 2B (EIF2BE/EIF2B5) in the same manner as
CC       glycogen synthase. In Wnt signaling, GSK3B forms a multimeric
CC       complex with APC, AXIN1 and CTNNB1/beta-catenin and phosphorylates
CC       the N-terminus of CTNNB1 leading to its degradation mediated by
CC       ubiquitin/proteasomes. Phosphorylates JUN at sites proximal to its
CC       DNA-binding domain, thereby reducing its affinity for DNA.
CC       Phosphorylates NFATC1/NFATC on conserved serine residues promoting
CC       NFATC1/NFATC nuclear export, shutting off NFATC1/NFATC gene
CC       regulation, and thereby opposing the action of calcineurin.
CC       Phosphorylates MAPT/TAU on 'Thr-548', decreasing significantly
CC       MAPT/TAU ability to bind and stabilize microtubules. MAPT/TAU is
CC       the principal component of neurofibrillary tangles in Alzheimer
CC       disease. Plays an important role in ERBB2-dependent stabilization
CC       of microtubules at the cell cortex. Phosphorylates MACF1,
CC       inhibiting its binding to microtubules which is critical for its
CC       role in bulge stem cell migration and skin wound repair. Probably
CC       regulates NF-kappa-B (NFKB1) at the transcriptional level and is
CC       required for the NF-kappa-B-mediated anti-apoptotic response to
CC       TNF-alpha (TNF/TNFA). Negatively regulates replication in
CC       pancreatic beta-cells, resulting in apoptosis, loss of beta-cells
CC       and diabetes. Through phosphorylation of the anti-apoptotic
CC       protein MCL1, may control cell apoptosis in response to growth
CC       factors deprivation. Phosphorylates MUC1 in breast cancer cells,
CC       decreasing the interaction of MUC1 with CTNNB1/beta-catenin. Is
CC       necessary for the establishment of neuronal polarity and axon
CC       outgrowth. Phosphorylates MARK2, leading to inhibit its activity.
CC       Phosphorylates SIK1 at 'Thr-182', leading to sustain its activity.
CC       Phosphorylates ZC3HAV1 which enhances its antiviral activity.
CC       Phosphorylates SNAI1, leading to its BTRC-triggered ubiquitination
CC       and proteasomal degradation. Phosphorylates SFPQ at 'Thr-687' upon
CC       T-cell activation. Phosphorylates NR1D1 st 'Ser-55' and 'Ser-59'
CC       and stabilizes it by protecting it from proteasomal degradation.
CC       Regulates the circadian clock via phosphorylation of the major
CC       clock components including ARNTL/BMAL1, CLOCK and PER2.
CC       Phosphorylates CLOCK AT 'Ser-427' and targets it for proteasomal
CC       degradation. Phosphorylates ARNTL/BMAL1 at 'Ser-17' and 'Ser-21'
CC       and primes it for ubiquitination and proteasomal degradation.
CC       Phosphorylates OGT at 'Ser-3' or 'Ser-4' which positively
CC       regulates its activity. Phosphorylates MYCN in neuroblastoma cells
CC       which may promote its degradation (PubMed:24391509).
CC       {ECO:0000269|PubMed:11430833, ECO:0000269|PubMed:12554650,
CC       ECO:0000269|PubMed:14690523, ECO:0000269|PubMed:15448698,
CC       ECO:0000269|PubMed:15647282, ECO:0000269|PubMed:16484495,
CC       ECO:0000269|PubMed:18348280, ECO:0000269|PubMed:1846781,
CC       ECO:0000269|PubMed:19946213, ECO:0000269|PubMed:20932480,
CC       ECO:0000269|PubMed:20937854, ECO:0000269|PubMed:22514281,
CC       ECO:0000269|PubMed:24391509, ECO:0000269|PubMed:8397507,
CC       ECO:0000269|PubMed:9072970, ECO:0000269|PubMed:9819408}.
CC   -!- CATALYTIC ACTIVITY: ATP + [tau protein] = ADP + [tau protein]
CC       phosphate.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activated by phosphorylation at Tyr-216. In
CC       response to insulin, inhibited by phosphorylation at Ser-9 by
CC       PKB/AKT1 and RPS6KA3; phosphorylation at this site causes a
CC       conformational change, preventing access of substrates to the
CC       active site. Inhibited by lithium. {ECO:0000269|PubMed:11749387,
CC       ECO:0000269|PubMed:12554650, ECO:0000269|PubMed:19366350,
CC       ECO:0000269|PubMed:8524413}.
CC   -!- SUBUNIT: Monomer. Interacts with ARRB2, DISC1 and ZBED3 (By
CC       similarity). Interacts with CABYR, MMP2, MUC1, NIN and PRUNE
CC       Interacts with AXIN1; the interaction mediates
CC       hyperphosphorylation of CTNNB1 leading to its ubiquitination and
CC       destruction. Interacts with and phosphorylates SNAI1. Interacts
CC       with DNM1L (via a C-terminal domain). Found in a complex composed
CC       of MACF1, APC, AXIN1, CTNNB1 and GSK3B (By similarity). Interacts
CC       with SGK3. Interacts with DAB2IP (via C2 domain); the interaction
CC       stimulates GSK3B kinase activation. Interacts (via C2 domain) with
CC       PPP2CA. Interacts with the CLOCK-ARNTL/BMAL1 heterodimer.
CC       Interacts with the ARNTL/BMAL1. Interacts with CTNND2
CC       (PubMed:19706605). Interacts with NCYM (PubMed:24391509).
CC       {ECO:0000250|UniProtKB:Q9WV60, ECO:0000269|PubMed:11004522,
CC       ECO:0000269|PubMed:12054501, ECO:0000269|PubMed:12554650,
CC       ECO:0000269|PubMed:15448698, ECO:0000269|PubMed:15647282,
CC       ECO:0000269|PubMed:15752768, ECO:0000269|PubMed:16428445,
CC       ECO:0000269|PubMed:17318175, ECO:0000269|PubMed:19493954,
CC       ECO:0000269|PubMed:19706605, ECO:0000269|PubMed:19946213,
CC       ECO:0000269|PubMed:20080667, ECO:0000269|PubMed:24391509,
CC       ECO:0000269|PubMed:9731200, ECO:0000269|PubMed:9819408}.
CC   -!- INTERACTION:
CC       P31749:AKT1; NbExp=3; IntAct=EBI-373586, EBI-296087;
CC       P31751:AKT2; NbExp=2; IntAct=EBI-373586, EBI-296058;
CC       O15169:AXIN1; NbExp=42; IntAct=EBI-373586, EBI-710484;
CC       O35625:Axin1 (xeno); NbExp=5; IntAct=EBI-373586, EBI-2365912;
CC       Q14DJ8:Axin1 (xeno); NbExp=2; IntAct=EBI-373586, EBI-4312125;
CC       Q96G01:BICD1; NbExp=7; IntAct=EBI-373586, EBI-1104509;
CC       P35222:CTNNB1; NbExp=15; IntAct=EBI-373586, EBI-491549;
CC       Q5VWQ8:DAB2IP; NbExp=2; IntAct=EBI-373586, EBI-2871881;
CC       Q5VWQ8-2:DAB2IP; NbExp=2; IntAct=EBI-373586, EBI-9543020;
CC       Q9NYF0:DACT1; NbExp=3; IntAct=EBI-373586, EBI-3951744;
CC       O75398:DEAF1; NbExp=2; IntAct=EBI-373586, EBI-718185;
CC       Q811T9:Disc1 (xeno); NbExp=4; IntAct=EBI-373586, EBI-2298259;
CC       P13807:GYS1; NbExp=3; IntAct=EBI-373586, EBI-740553;
CC       O75581:LRP6; NbExp=4; IntAct=EBI-373586, EBI-910915;
CC       Q5S007:LRRK2; NbExp=7; IntAct=EBI-373586, EBI-5323863;
CC       P63085:Mapk1 (xeno); NbExp=2; IntAct=EBI-373586, EBI-397697;
CC       P10636:MAPT; NbExp=2; IntAct=EBI-373586, EBI-366182;
CC       P10636-8:MAPT; NbExp=9; IntAct=EBI-373586, EBI-366233;
CC       Q8N4C6:NIN; NbExp=3; IntAct=EBI-373586, EBI-1164022;
CC       P17612:PRKACA; NbExp=5; IntAct=EBI-373586, EBI-476586;
CC       Q01201:RELB; NbExp=4; IntAct=EBI-373586, EBI-357837;
CC       Q15797:SMAD1; NbExp=2; IntAct=EBI-373586, EBI-1567153;
CC       O95863:SNAI1; NbExp=5; IntAct=EBI-373586, EBI-1045459;
CC       P37840:SNCA; NbExp=2; IntAct=EBI-373586, EBI-985879;
CC       Q6J9G0:STYK1; NbExp=2; IntAct=EBI-373586, EBI-6424915;
CC       P04637:TP53; NbExp=3; IntAct=EBI-373586, EBI-366083;
CC       Q14134:TRIM29; NbExp=2; IntAct=EBI-373586, EBI-702370;
CC       O95071:UBR5; NbExp=8; IntAct=EBI-373586, EBI-358329;
CC       P63104:YWHAZ; NbExp=4; IntAct=EBI-373586, EBI-347088;
CC       Q8IX07:ZFPM1; NbExp=2; IntAct=EBI-373586, EBI-3942619;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane. Note=The
CC       phosphorylated form shows localization to cytoplasm and cell
CC       membrane. The MEMO1-RHOA-DIAPH1 signaling pathway controls
CC       localization of the phosphorylated form to the cell membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=GSK-3beta1;
CC         IsoId=P49841-1; Sequence=Displayed;
CC       Name=2; Synonyms=GSK-3beta2, neuron-specific;
CC         IsoId=P49841-2; Sequence=VSP_004790;
CC         Note=May play a specific role in axon growth and neurite
CC         outgrowth. Reduced binding to AXIN1, reduced ability to
CC         phosphorylate MAPT/TAU. {ECO:0000269|PubMed:20067585};
CC   -!- TISSUE SPECIFICITY: Expressed in testis, thymus, prostate and
CC       ovary and weakly expressed in lung, brain and kidney. Colocalizes
CC       with EIF2AK2/PKR and TAU in the Alzheimer disease (AD) brain.
CC       {ECO:0000269|PubMed:21029237}.
CC   -!- PTM: Phosphorylated by AKT1 and ILK1. Upon insulin-mediated
CC       signaling, the activated PKB/AKT1 protein kinase phosphorylates
CC       and desactivates GSK3B, resulting in the dephosphorylation and
CC       activation of GYS1. Activated by phosphorylation at Tyr-216.
CC       {ECO:0000269|PubMed:12054501, ECO:0000269|PubMed:12554650,
CC       ECO:0000269|PubMed:16484495, ECO:0000269|PubMed:20937854,
CC       ECO:0000269|PubMed:21029237, ECO:0000269|PubMed:8250835}.
CC   -!- PTM: Mono-ADP-ribosylation by PARP10 negatively regulates kinase
CC       activity.
CC   -!- MISCELLANEOUS: Higher expression and activity of GSK3B are found
CC       in the skeletal muscle (vastus lateralis) of patients with type 2
CC       diabetes (PubMed:10868943). Several potent GSK3 (GSK3A and GSK3B)
CC       inhibitors have been identified and characterized in preclinical
CC       models for treatments of type 2 diabetes (PubMed:19366350).
CC       {ECO:0000305|PubMed:10868943, ECO:0000305|PubMed:19366350}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC
CC       Ser/Thr protein kinase family. GSK-3 subfamily. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/GSK3BID40761ch3q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L33801; AAA66475.1; -; mRNA.
DR   EMBL; CH471052; EAW79533.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79536.1; -; Genomic_DNA.
DR   EMBL; BC000251; AAH00251.1; -; mRNA.
DR   EMBL; BC012760; AAH12760.1; -; mRNA.
DR   EMBL; AF074333; AAD48517.1; -; Genomic_DNA.
DR   EMBL; AF098789; AAC69340.1; -; Genomic_DNA.
DR   CCDS; CCDS2996.1; -. [P49841-2]
DR   CCDS; CCDS54628.1; -. [P49841-1]
DR   PIR; S53324; S53324.
DR   RefSeq; NP_001139628.1; NM_001146156.1. [P49841-1]
DR   RefSeq; NP_002084.2; NM_002093.3. [P49841-2]
DR   UniGene; Hs.445733; -.
DR   PDB; 1GNG; X-ray; 2.60 A; A/B=27-393.
DR   PDB; 1H8F; X-ray; 2.80 A; A/B=35-386.
DR   PDB; 1I09; X-ray; 2.70 A; A/B=1-420.
DR   PDB; 1J1B; X-ray; 1.80 A; A/B=1-420.
DR   PDB; 1J1C; X-ray; 2.10 A; A/B=1-420.
DR   PDB; 1O6K; X-ray; 1.70 A; C=3-12.
DR   PDB; 1O6L; X-ray; 1.60 A; C=3-12.
DR   PDB; 1O9U; X-ray; 2.40 A; A=35-384.
DR   PDB; 1PYX; X-ray; 2.40 A; A/B=1-420.
DR   PDB; 1Q3D; X-ray; 2.20 A; A/B=2-420.
DR   PDB; 1Q3W; X-ray; 2.30 A; A/B=2-420.
DR   PDB; 1Q41; X-ray; 2.10 A; A/B=2-420.
DR   PDB; 1Q4L; X-ray; 2.77 A; A/B=2-420.
DR   PDB; 1Q5K; X-ray; 1.94 A; A/B=7-420.
DR   PDB; 1R0E; X-ray; 2.25 A; A/B=35-420.
DR   PDB; 1UV5; X-ray; 2.80 A; A=35-384.
DR   PDB; 2JDO; X-ray; 1.80 A; C=3-12.
DR   PDB; 2JDR; X-ray; 2.30 A; C=3-12.
DR   PDB; 2JLD; X-ray; 2.35 A; A/B=1-420.
DR   PDB; 2O5K; X-ray; 3.20 A; A=29-393.
DR   PDB; 2OW3; X-ray; 2.80 A; A/B=35-386.
DR   PDB; 2UW9; X-ray; 2.10 A; C=3-12.
DR   PDB; 2X39; X-ray; 1.93 A; C=3-12.
DR   PDB; 2XH5; X-ray; 2.72 A; C=3-12.
DR   PDB; 3CQU; X-ray; 2.20 A; C=3-12.
DR   PDB; 3CQW; X-ray; 2.00 A; C=3-12.
DR   PDB; 3DU8; X-ray; 2.20 A; A/B=1-420.
DR   PDB; 3E87; X-ray; 2.30 A; C/D=3-12.
DR   PDB; 3E88; X-ray; 2.50 A; C/D=3-12.
DR   PDB; 3E8D; X-ray; 2.70 A; C/D=3-12.
DR   PDB; 3F7Z; X-ray; 2.40 A; A/B=35-383.
DR   PDB; 3F88; X-ray; 2.60 A; A/B=35-383.
DR   PDB; 3GB2; X-ray; 2.40 A; A=34-383.
DR   PDB; 3I4B; X-ray; 2.30 A; A/B=7-420.
DR   PDB; 3L1S; X-ray; 2.90 A; A/B=7-420.
DR   PDB; 3M1S; X-ray; 3.13 A; A/B=1-420.
DR   PDB; 3MV5; X-ray; 2.47 A; C=3-12.
DR   PDB; 3OW4; X-ray; 2.60 A; C/D=3-12.
DR   PDB; 3PUP; X-ray; 2.99 A; A/B=1-420.
DR   PDB; 3Q3B; X-ray; 2.70 A; A/B=2-420.
DR   PDB; 3QKK; X-ray; 2.30 A; C=3-12.
DR   PDB; 3SAY; X-ray; 2.23 A; A/B=1-420.
DR   PDB; 3SD0; X-ray; 2.70 A; A/B=35-384.
DR   PDB; 3ZDI; X-ray; 2.64 A; A=35-384.
DR   PDB; 3ZRK; X-ray; 2.37 A; A/B=23-393.
DR   PDB; 3ZRL; X-ray; 2.48 A; A/B=23-393.
DR   PDB; 3ZRM; X-ray; 2.49 A; A/B=23-393.
DR   PDB; 4ACC; X-ray; 2.21 A; A/B=1-420.
DR   PDB; 4ACD; X-ray; 2.60 A; A/B=1-420.
DR   PDB; 4ACG; X-ray; 2.60 A; A/B=1-420.
DR   PDB; 4ACH; X-ray; 2.60 A; A/B=1-420.
DR   PDB; 4AFJ; X-ray; 1.98 A; A/B=27-393.
DR   PDB; 4B7T; X-ray; 2.77 A; A=35-384.
DR   PDB; 4DIT; X-ray; 2.60 A; A=27-393.
DR   PDB; 4EKK; X-ray; 2.80 A; C/D=3-12.
DR   PDB; 4IQ6; X-ray; 3.12 A; A/B=1-420.
DR   PDB; 4J1R; X-ray; 2.70 A; A/B/C/D=1-420.
DR   PDB; 4J71; X-ray; 2.31 A; A/B=1-420.
DR   PDB; 4NM0; X-ray; 2.50 A; A=1-383.
DR   PDB; 4NM3; X-ray; 2.10 A; A=1-383.
DR   PDB; 4NM5; X-ray; 2.30 A; A=13-383.
DR   PDB; 4NM7; X-ray; 2.30 A; A=13-383.
DR   PDB; 4PTC; X-ray; 2.71 A; A/B=1-420.
DR   PDB; 4PTE; X-ray; 2.03 A; A/B=1-420.
DR   PDB; 4PTG; X-ray; 2.36 A; A/B=1-420.
DR   PDBsum; 1GNG; -.
DR   PDBsum; 1H8F; -.
DR   PDBsum; 1I09; -.
DR   PDBsum; 1J1B; -.
DR   PDBsum; 1J1C; -.
DR   PDBsum; 1O6K; -.
DR   PDBsum; 1O6L; -.
DR   PDBsum; 1O9U; -.
DR   PDBsum; 1PYX; -.
DR   PDBsum; 1Q3D; -.
DR   PDBsum; 1Q3W; -.
DR   PDBsum; 1Q41; -.
DR   PDBsum; 1Q4L; -.
DR   PDBsum; 1Q5K; -.
DR   PDBsum; 1R0E; -.
DR   PDBsum; 1UV5; -.
DR   PDBsum; 2JDO; -.
DR   PDBsum; 2JDR; -.
DR   PDBsum; 2JLD; -.
DR   PDBsum; 2O5K; -.
DR   PDBsum; 2OW3; -.
DR   PDBsum; 2UW9; -.
DR   PDBsum; 2X39; -.
DR   PDBsum; 2XH5; -.
DR   PDBsum; 3CQU; -.
DR   PDBsum; 3CQW; -.
DR   PDBsum; 3DU8; -.
DR   PDBsum; 3E87; -.
DR   PDBsum; 3E88; -.
DR   PDBsum; 3E8D; -.
DR   PDBsum; 3F7Z; -.
DR   PDBsum; 3F88; -.
DR   PDBsum; 3GB2; -.
DR   PDBsum; 3I4B; -.
DR   PDBsum; 3L1S; -.
DR   PDBsum; 3M1S; -.
DR   PDBsum; 3MV5; -.
DR   PDBsum; 3OW4; -.
DR   PDBsum; 3PUP; -.
DR   PDBsum; 3Q3B; -.
DR   PDBsum; 3QKK; -.
DR   PDBsum; 3SAY; -.
DR   PDBsum; 3SD0; -.
DR   PDBsum; 3ZDI; -.
DR   PDBsum; 3ZRK; -.
DR   PDBsum; 3ZRL; -.
DR   PDBsum; 3ZRM; -.
DR   PDBsum; 4ACC; -.
DR   PDBsum; 4ACD; -.
DR   PDBsum; 4ACG; -.
DR   PDBsum; 4ACH; -.
DR   PDBsum; 4AFJ; -.
DR   PDBsum; 4B7T; -.
DR   PDBsum; 4DIT; -.
DR   PDBsum; 4EKK; -.
DR   PDBsum; 4IQ6; -.
DR   PDBsum; 4J1R; -.
DR   PDBsum; 4J71; -.
DR   PDBsum; 4NM0; -.
DR   PDBsum; 4NM3; -.
DR   PDBsum; 4NM5; -.
DR   PDBsum; 4NM7; -.
DR   PDBsum; 4PTC; -.
DR   PDBsum; 4PTE; -.
DR   PDBsum; 4PTG; -.
DR   DisProt; DP00385; -.
DR   ProteinModelPortal; P49841; -.
DR   SMR; P49841; 6-386.
DR   BioGrid; 109187; 254.
DR   DIP; DIP-878N; -.
DR   IntAct; P49841; 189.
DR   MINT; MINT-105006; -.
DR   STRING; 9606.ENSP00000324806; -.
DR   BindingDB; P49841; -.
DR   ChEMBL; CHEMBL2095188; -.
DR   DrugBank; DB01356; Lithium.
DR   GuidetoPHARMACOLOGY; 2030; -.
DR   PhosphoSite; P49841; -.
DR   BioMuta; GSK3B; -.
DR   DMDM; 20455502; -.
DR   MaxQB; P49841; -.
DR   PaxDb; P49841; -.
DR   PRIDE; P49841; -.
DR   DNASU; 2932; -.
DR   Ensembl; ENST00000264235; ENSP00000264235; ENSG00000082701.
DR   Ensembl; ENST00000316626; ENSP00000324806; ENSG00000082701. [P49841-2]
DR   GeneID; 2932; -.
DR   KEGG; hsa:2932; -.
DR   UCSC; uc003edn.3; human. [P49841-2]
DR   UCSC; uc003edo.3; human. [P49841-1]
DR   CTD; 2932; -.
DR   GeneCards; GC03M119540; -.
DR   HGNC; HGNC:4617; GSK3B.
DR   HPA; CAB016263; -.
DR   HPA; HPA028017; -.
DR   MIM; 605004; gene.
DR   neXtProt; NX_P49841; -.
DR   PharmGKB; PA29009; -.
DR   eggNOG; COG0515; -.
DR   GeneTree; ENSGT00520000055635; -.
DR   HOGENOM; HOG000233017; -.
DR   HOVERGEN; HBG014652; -.
DR   InParanoid; P49841; -.
DR   KO; K03083; -.
DR   OMA; NAGERVQ; -.
DR   OrthoDB; EOG7TF78V; -.
DR   PhylomeDB; P49841; -.
DR   TreeFam; TF101104; -.
DR   BRENDA; 2.7.11.26; 2681.
DR   Reactome; REACT_11063; Degradation of beta-catenin by the destruction complex.
DR   Reactome; REACT_11065; Beta-catenin phosphorylation cascade.
DR   Reactome; REACT_12564; AKT phosphorylates targets in the cytosol.
DR   Reactome; REACT_19199; CRMPs in Sema3A signaling.
DR   Reactome; REACT_263893; truncations of AMER1 destabilize the destruction complex.
DR   Reactome; REACT_263992; APC truncation mutants have impaired AXIN binding.
DR   Reactome; REACT_264030; AXIN missense mutants destabilize the destruction complex.
DR   Reactome; REACT_264034; disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   Reactome; REACT_264092; misspliced GSK3beta mutants stabilize beta-catenin.
DR   Reactome; REACT_264127; T41 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; REACT_264295; S45 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; REACT_264487; Regulation of HSF1-mediated heat shock response.
DR   Reactome; REACT_264581; S33 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; REACT_264636; S37 mutants of beta-catenin aren't phosphorylated.
DR   Reactome; REACT_267700; Degradation of GLI2 by the proteasome.
DR   Reactome; REACT_268366; GLI3 is processed to GLI3R by the proteasome.
DR   Reactome; REACT_355468; Constitutive Signaling by AKT1 E17K in Cancer.
DR   SignaLink; P49841; -.
DR   ChiTaRS; GSK3B; human.
DR   EvolutionaryTrace; P49841; -.
DR   GeneWiki; GSK3B; -.
DR   GenomeRNAi; 2932; -.
DR   NextBio; 11619; -.
DR   PRO; PR:P49841; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; P49841; -.
DR   CleanEx; HS_GSK3B; -.
DR   ExpressionAtlas; P49841; baseline and differential.
DR   Genevisible; P49841; HS.
DR   GO; GO:0030877; C:beta-catenin destruction complex; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0043198; C:dendritic shaft; IEA:Ensembl.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0097481; C:neuronal postsynaptic density; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0030529; C:ribonucleoprotein complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL.
DR   GO; GO:0016301; F:kinase activity; IDA:UniProtKB.
DR   GO; GO:0051059; F:NF-kappaB binding; IPI:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IDA:MGI.
DR   GO; GO:0034236; F:protein kinase A catalytic subunit binding; IPI:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0050321; F:tau-protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IC:UniProtKB.
DR   GO; GO:0044337; P:canonical Wnt signaling pathway involved in positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; IEA:Ensembl.
DR   GO; GO:0034605; P:cellular response to heat; TAS:Reactome.
DR   GO; GO:0036016; P:cellular response to interleukin-3; ISS:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; IMP:UniProtKB.
DR   GO; GO:0006983; P:ER overload response; IDA:MGI.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; ISS:UniProtKB.
DR   GO; GO:0045444; P:fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0005977; P:glycogen metabolic process; IDA:BHF-UCL.
DR   GO; GO:0021766; P:hippocampus development; IMP:BHF-UCL.
DR   GO; GO:0044027; P:hypermethylation of CpG island; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:Reactome.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:MGI.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; IEA:Ensembl.
DR   GO; GO:0007520; P:myoblast fusion; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:MGI.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; TAS:UniProtKB.
DR   GO; GO:0010614; P:negative regulation of cardiac muscle hypertrophy; IEA:Ensembl.
DR   GO; GO:2000466; P:negative regulation of glycogen (starch) synthase activity; TAS:UniProtKB.
DR   GO; GO:0045719; P:negative regulation of glycogen biosynthetic process; TAS:UniProtKB.
DR   GO; GO:0014043; P:negative regulation of neuron maturation; IEA:Ensembl.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0051534; P:negative regulation of NFAT protein import into nucleus; IMP:UniProtKB.
DR   GO; GO:0032091; P:negative regulation of protein binding; IDA:BHF-UCL.
DR   GO; GO:0031333; P:negative regulation of protein complex assembly; IMP:BHF-UCL.
DR   GO; GO:2000077; P:negative regulation of type B pancreatic cell development; TAS:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0009887; P:organ morphogenesis; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0045773; P:positive regulation of axon extension; IEA:Ensembl.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; TAS:Reactome.
DR   GO; GO:0001954; P:positive regulation of cell-matrix adhesion; IMP:BHF-UCL.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IMP:BHF-UCL.
DR   GO; GO:1901030; P:positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway; ISS:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IEA:Ensembl.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0032092; P:positive regulation of protein binding; ISS:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IC:BHF-UCL.
DR   GO; GO:0031334; P:positive regulation of protein complex assembly; IDA:BHF-UCL.
DR   GO; GO:0046827; P:positive regulation of protein export from nucleus; IDA:MGI.
DR   GO; GO:2000738; P:positive regulation of stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006611; P:protein export from nucleus; IEA:Ensembl.
DR   GO; GO:0035372; P:protein localization to microtubule; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0000320; P:re-entry into mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome.
DR   GO; GO:0006349; P:regulation of gene expression by genetic imprinting; IEA:Ensembl.
DR   GO; GO:0032886; P:regulation of microtubule-based process; IMP:UniProtKB.
DR   GO; GO:0071109; P:superior temporal gyrus development; IMP:BHF-UCL.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR002290; Ser/Thr_dual-sp_kinase.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Alternative splicing;
KW   Alzheimer disease; ATP-binding; Biological rhythms;
KW   Carbohydrate metabolism; Cell membrane; Complete proteome; Cytoplasm;
KW   Developmental protein; Diabetes mellitus; Differentiation;
KW   Glycogen metabolism; Kinase; Membrane; Neurogenesis;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Signal transduction inhibitor;
KW   Transferase; Wnt signaling pathway.
FT   CHAIN         1    420       Glycogen synthase kinase-3 beta.
FT                                /FTId=PRO_0000085980.
FT   DOMAIN       56    340       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      62     70       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    181    181       Proton acceptor.
FT   BINDING      85     85       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       9      9       Phosphoserine; by PKB/AKT1, RPS6KA3 and
FT                                SGK3. {ECO:0000269|PubMed:12054501,
FT                                ECO:0000269|PubMed:16484495,
FT                                ECO:0000269|PubMed:20937854,
FT                                ECO:0000269|PubMed:24391509,
FT                                ECO:0000269|PubMed:8250835}.
FT   MOD_RES     216    216       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:12554650}.
FT   MOD_RES     389    389       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9WV60}.
FT   MOD_RES     390    390       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   MOD_RES     402    402       Phosphothreonine.
FT                                {ECO:0000269|PubMed:18691976}.
FT   VAR_SEQ     303    303       K -> KDSSGTGHFTSGVR (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_004790.
FT   MUTAGEN       9      9       S->A: Loss of phosphorylation; No
FT                                inhibition of activity and constitutively
FT                                active. {ECO:0000269|PubMed:7980435}.
FT   MUTAGEN      96     96       R->A: Prevents the phosphorylation of
FT                                phosphate-primed glycogen synthase.
FT                                {ECO:0000269|PubMed:11430833}.
FT   MUTAGEN     128    128       L->A: Abolishes activity toward AXIN1.
FT                                {ECO:0000269|PubMed:11430833}.
FT   CONFLICT     28     28       V -> G (in Ref. 4; AAD48517).
FT                                {ECO:0000305}.
FT   CONFLICT    350    350       L -> H (in Ref. 1; AAA66475).
FT                                {ECO:0000305}.
FT   STRAND       10     12       {ECO:0000244|PDB:2JDO}.
FT   STRAND       26     30       {ECO:0000244|PDB:1J1B}.
FT   STRAND       32     34       {ECO:0000244|PDB:4NM5}.
FT   STRAND       38     48       {ECO:0000244|PDB:1J1B}.
FT   STRAND       52     64       {ECO:0000244|PDB:1J1B}.
FT   STRAND       66     75       {ECO:0000244|PDB:1J1B}.
FT   TURN         76     78       {ECO:0000244|PDB:1J1B}.
FT   STRAND       81     88       {ECO:0000244|PDB:1J1B}.
FT   STRAND       91     93       {ECO:0000244|PDB:1Q5K}.
FT   HELIX        96    102       {ECO:0000244|PDB:1J1B}.
FT   STRAND      112    120       {ECO:0000244|PDB:1J1B}.
FT   TURN        121    124       {ECO:0000244|PDB:1J1B}.
FT   STRAND      125    133       {ECO:0000244|PDB:1J1B}.
FT   STRAND      136    138       {ECO:0000244|PDB:1Q5K}.
FT   HELIX       139    148       {ECO:0000244|PDB:1J1B}.
FT   HELIX       155    173       {ECO:0000244|PDB:1J1B}.
FT   TURN        174    176       {ECO:0000244|PDB:1J1B}.
FT   HELIX       184    186       {ECO:0000244|PDB:1J1B}.
FT   STRAND      187    190       {ECO:0000244|PDB:1J1B}.
FT   TURN        191    194       {ECO:0000244|PDB:1J1B}.
FT   STRAND      195    198       {ECO:0000244|PDB:1J1B}.
FT   STRAND      209    211       {ECO:0000244|PDB:4DIT}.
FT   HELIX       220    222       {ECO:0000244|PDB:4AFJ}.
FT   HELIX       225    228       {ECO:0000244|PDB:1J1B}.
FT   HELIX       237    252       {ECO:0000244|PDB:1J1B}.
FT   HELIX       262    273       {ECO:0000244|PDB:1J1B}.
FT   HELIX       278    284       {ECO:0000244|PDB:1J1B}.
FT   HELIX       286    288       {ECO:0000244|PDB:4NM3}.
FT   STRAND      289    291       {ECO:0000244|PDB:4ACC}.
FT   HELIX       301    304       {ECO:0000244|PDB:1J1B}.
FT   HELIX       311    320       {ECO:0000244|PDB:1J1B}.
FT   HELIX       325    327       {ECO:0000244|PDB:1J1B}.
FT   HELIX       331    335       {ECO:0000244|PDB:1J1B}.
FT   HELIX       338    344       {ECO:0000244|PDB:1J1B}.
FT   STRAND      345    347       {ECO:0000244|PDB:1UV5}.
FT   HELIX       364    367       {ECO:0000244|PDB:1J1B}.
FT   HELIX       371    373       {ECO:0000244|PDB:1J1B}.
FT   HELIX       374    377       {ECO:0000244|PDB:1J1B}.
FT   TURN        380    383       {ECO:0000244|PDB:1J1B}.
SQ   SEQUENCE   420 AA;  46744 MW;  4ACC24D00CDBB9C3 CRC64;
     MSGRPRTTSF AESCKPVQQP SAFGSMKVSR DKDGSKVTTV VATPGQGPDR PQEVSYTDTK
     VIGNGSFGVV YQAKLCDSGE LVAIKKVLQD KRFKNRELQI MRKLDHCNIV RLRYFFYSSG
     EKKDEVYLNL VLDYVPETVY RVARHYSRAK QTLPVIYVKL YMYQLFRSLA YIHSFGICHR
     DIKPQNLLLD PDTAVLKLCD FGSAKQLVRG EPNVSYICSR YYRAPELIFG ATDYTSSIDV
     WSAGCVLAEL LLGQPIFPGD SGVDQLVEII KVLGTPTREQ IREMNPNYTE FKFPQIKAHP
     WTKVFRPRTP PEAIALCSRL LEYTPTARLT PLEACAHSFF DELRDPNVKL PNGRDTPALF
     NFTTQELSSN PPLATILIPP HARIQAAAST PTNATAASDA NTGDRGQTNN AASASASNST
//
